🤝 #IRBBarcelona Group Leader Cristina Mayor-Ruiz has co-authored a Perspective in #MolecularCell proposing the creation of a #EuropeanAlliance to accelerate the development of proximity-induced therapies.

More information here 🔗 www.irbbarcelona.org/en/news/scie...

🧪 #TargetedProteinDegradation

📷 Photo 51 — the image that changed the course of science.

Taken by British chemist and crystallographer #RosalindFranklin (born on this day in 1920) and Raymond Gosling, this X-ray diffraction image of DNA was the key to unlocking the double helix structure.

#WomeninSTEM

🔬Check out this recent spotlight in #MolecularCell, co-authored by Rory Whelan
Ferran José Duran & @crismayorruiz.bsky.social— Mutations that stick: Unexpected discovery of molecular glue mimicry👇 

➡️ https://f.mtr.cool/zbljytwpcx

#ChemBio #MolecularGlue #MolecularGlues

🧪

👇🧪

Congrats Will & team!!

🟣 On #WomensDay, we recognize the incredible women of #IRBBarcelona! Researchers, technicians, managers, and other professionals whose talent and dedication push the boundaries of knowledge.

Your work fuels discovery and paves the way for future generations of women in science.

Thank you! 🙌

#8M

🧪 #Barcelona

📌 La Dra. Ana Domostegui desarrolla un nuevo tipo de fármacos innovadores, denominados fármacos degradadores de proteínas, para el tratamiento del #CáncerdePáncreas.

📌 PROTECT:

En el marco de @cancergrand.bsky.social, el proyecto liderado por la Dra. @crismayorruiz.bsky.social desarrollará fármacos degradadores de proteínas para luchar contra los tumores pediátricos.

🟢 Ha sido un honor asistir hoy a la presentación de las Ayudas 2024 de la Asociación Española Contra el Cáncer.

¡Gracias Asociación Española contra el Cáncer por acompañarnos en este compromiso! Cada paso juntos nos acerca a un futuro sin #cáncer.

Descubre los proyectos del @irbbarcelona.org:

🧵👇

Avui hem tingut l’honor de rebre la visita de la consellera de Salut, Dra. Olga Pané. Ha conegut de primera mà els plans de futur de l'Institut i la importància dels nous laboratoris TRIP, una innovadora forma d'apropar #recerca fonamental i clínica.

Gràcies, consellera!

Hello, Blueskyers! Here's a comprehensive Starter Pack featuring all the IRB Barcelona faculty and affiliated members currently active on Bluesky. Keep an eye on this space—we'll be regularly updating it as more of our researchers join the platform. Thanks for following us!

go.bsky.app/6QPdeJj

Happy #WomenScienceDay!
@irbbarcelona.org
🧪
youtube.com/shorts/p3rRs...

We are creating a dedicated website to honor the memory of Dr. Joan Guinovart and celebrate his remarkable legacy✨ 

Contribute by sharing your message through this form: ➡️ http://shorturl.at/YQn1l 

Join us in paying tribute to his extraordinary impact.

🧪

👋👋

The office had never been so busy!!😅

Our lab wishes you all a Merry Christmas!

We finish the scientific year at the @irbbarcelona.org Christmas party with the best costume ever!! 🤣🤣🤣

🧪

Huge congrats to #Alberto & #Inés, co-first authors! Amazing team effort with many other friends: Toni, Pep, Carlos, Caro, etc. @irbbarcelona.bsky.social

Targeted KRAS(G12V) degradation elicits efficient and durable lung adenocarcinoma regression in vivo Recent drug discovery breakthroughs led to the approval of KRASG12C inhibitors in lung adenocarcinoma (LUAD). Unfortunately, clinical responses remain limited due to rapid resistance onset. Proteolysi...

Specifically, this allowed us to:
(i) Study the therapeutic efficacy of KRAS(G12V)-targeted degradation in vivo
(ii) Dissect tumor regression mechanisms (cell-intrinsic/extrinsic)
(iii) Investigate resistance

Curious to learn more? Take a look! www.biorxiv.org/content/10.1...

Chemical, tumor-specific modulation of KRAS(G12V) protein abundance served here to probe the therapeutic potential of oncoprotein degradation and to selectively dissect the biological outcomes!

We developed a preclinical mouse model of lung adenocarcinoma in which we can induce selective KRAS(G12V) degradation in vivo, leveraging the dTAG system

Targeted KRAS(G12V) degradation elicits efficient and durable lung adenocarcinoma regression in vivo Recent drug discovery breakthroughs led to the approval of KRASG12C inhibitors in lung adenocarcinoma (LUAD). Unfortunately, clinical responses remain limited due to rapid resistance onset. Proteolysi...

Hi BlueSky world!
We are thrilled to share our new preprint around oncoprotein degradation in vivo —a fantastic collaboration with our friends in Salamanca #lab_santamaria #ciccancer! 😃
@irbbarcelona.bsky.social #TPD #KRAS

👇
www.biorxiv.org/content/10.1...

Women in chemistry starter pack here: go.bsky.app/LjumNEg
#ChemSky
please repost :D

#ChemSky #realtimechem #FluorescenceFriday

📯📯 Chemical Biology starter pack 📯📯
140 PIs & groups posting primary research in chemical biology.

Please reskeet (?) & reply to this post if you want to be added!
go.bsky.app/KLrTWoj

Let's make ChemBioSky even greater again!

#realtimechem #FluorescenceFriday #chemsky #chemtwitter #AgentOrange

Check out this list of ubiquitin and Ubl profiles to follow. Repost if you want me to add you to it. Let’s create a good community here ☁️ go.bsky.app/3VPQofn